Drug Trial Radar · NCT00312806
Effect of Pantoprazole on the Symptoms of Acid Reflux Disease in Adult Patients (BY1023/M3-341)
Last checked: Nov 19, 2026Latest source record: May 7, 2012 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
2,000
Planned (sponsor's estimate)
Start
May 2006
Primary completion
Mar 2007
Study completion Jul 2007
Sponsor
- Lead sponsor
- TakedaTakeda (TAK)
- Sponsor type
- Industry
- First posted
- Apr 11, 2006
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The aim of the present study is to identify factors (such as symptom patterns and symptom scores) that influence the response to treatment with pantoprazole using different evaluation methods (e.g., ReQuest™ questionnaire, patient and investigator assessment). Pantoprazole will be administered once daily in the morning at one dose level. The study duration consists of a treatment period of 8 weeks. The study will provide further data on safety and tolerability of pantoprazole.
Conditions
- Gastroesophageal Reflux Disease (GERD)
Interventions
PantoprazoleDrug
Pantoprazole 40 mg o.d.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Response to treatment with pantoprazole at week 8, as measured by the questionnaire ReQuest™Time frame: 8 weeks
Locations
186 sites in 22 countries. Site status is shown where the registry gives one.
Altana Pharma/Nycomed
Buenos Aires, Argentina
Altana Pharma/Nycomed
Buenos Aires, Argentina
Altana Pharma/Nycomed
Buenos Aires, Argentina
Altana Pharma/Nycomed
La Plata, Argentina
Altana Pharma/Nycomed
Bedford Park SA, Australia
Altana Pharma/Nycomed
Bondi Junction, Australia
Altana Pharma/Nycomed
Fitzroy, Australia
Altana Pharma/Nycomed
Footscray, Australia
Altana Pharma/Nycomed
Fremantle, WA, Australia
Altana Pharma/Nycomed
Kippa_ring, Australia
Altana Pharma/Nycomed
Melbourne, Australia
Altana Pharma/Nycomed
NSW, Australia
Altana Pharma/Nycomed
Penrith, NSW, Australia
Altana Pharma/Nycomed
Phrahran, Australia
Altana Pharma/Nycomed
Deutschlandsberg, Austria
Altana Pharma/Nycomed
Feldbach, Austria
Altana Pharma/Nycomed
Graz, Austria
Altana Pharma/Nycomed
Krems A. D. Donau, Austria
Altana Pharma/Nycomed
Lilienfeld, Austria
Altana Pharma/Nycomed
Sankt Pölten, Austria
Altana Pharma/Nycomed
Vienna, Austria
Altana Pharma/Nycomed
Vienna, Austria
Altana Pharma/Nycomed
Vienna, Austria
Altana Pharma/Nycomed
Vienna, Austria
Altana Pharma/Nycomed
Vienna, Austria
Altana Pharma/Nycomed
Vienna, Austria
Altana Pharma/Nycomed
Bouge, Belgium
Altana Pharma/Nycomed
Brussels, Belgium
Altana Pharma/Nycomed
Brussels, Belgium
Altana Pharma/Nycomed
Brussels, Belgium
Altana Pharma/Nycomed
Brussels, Belgium
Altana Pharma/Nycomed
Edegem, Belgium
Altana Pharma/Nycomed
Eupen, Belgium
Altana Pharma/Nycomed
Ghent, Belgium
Altana Pharma/Nycomed
Jette, Belgium
Altana Pharma/Nycomed
Kortrijk, Belgium
Altana Pharma/Nycomed
Leuven, Belgium
Altana Pharma/Nycomed
Merksem, Belgium
Altana Pharma/Nycomed
Ostend, Belgium
Altana Pharma/Nycomed
Saint Niklaas, Belgium
Showing 40 of 186 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.